Embozene Color-Advanced Microspheres
Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia. 510(k) K180102, from Boston Scientific (Maple Grove, MN). Product code NOY, class 2.
As of Nov 17, 2026, K180102 is an FDA 510(k) held by Boston Scientific, substantially equivalent on Apr 19, 2018 after 93 days, with no recalls tied to it in FDA's recall database.
- Substantially equivalent: Apr 19, 2018
- Review time: 93 days
- Recalls: 0
- Cited as a predicate by: 1 device
Indications for Use
As the 510(k) summary states them, read from FDA's summary PDFEmbozene Microspheres are intended for embolization of arteriovenous malformations and hypervascular tumors, including uterine fibroids (UFE) and hepatoma, and for embolization of prostatic arteries (PAE) for symptomatic benign prostatic hyperplasia (BPH). This device is not intended for neurovascular use.
Predicate Devices
The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF- Embosphere MicrospheresDEN160040 · Biosphere Medical, S.A. · Jun 21, 2017
Cited as a Predicate
1 later 510(k) summary names this device as a predicate- Embozene Color-Advanced MicrospheresK242608 · Varian Medical Systems, Inc. · Jan 17, 2025
Other NOY Clearances
The newest 510(k)s for the same product code; see every NOY device- Bead Block (100 - 300µm, 1ml), Bead Block (300 - 500µm, 1ml), Bead Block (500 - 700µm,…K203276 · Biocompatibles UK Ltd (Part of Boston Scientific Corporation · Apr 20, 2021
Record
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Jan 16, 2018
- Review panel
- Gastroenterology, Urology
- Regulation
- 21 CFR 876.5550
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files